Documented infections and febrile episodes during 12 weeks after initiation of treatment
| . | G-CSF− group . | G-CSF+ group . | P . |
|---|---|---|---|
| n | 47 | 48 | — |
| No. of patients with documented infections*; severe infection, grade 3 or 4 | 19; 5 | 28; 8 | .07; .30 |
| Accumulated number of infectious events† | 31 | 39 | .07 |
| Bacteremia | 5 | 7 | — |
| Pneumonia | 1 | 3 | — |
| Upper respiratory tract infection | 5 | 6 | — |
| Intestinal infection | 2 | 4 | — |
| Urinary tract infection | 1 | 0 | — |
| Genital infection | 0 | 2 | — |
| Cellulitis | 1 | 2 | — |
| Herpes zoster | 1 | 0 | — |
| Herpes simplex | 2 | 4 | — |
| Fungal infection | 0 | 3 | — |
| Gingivitis | 1 | 0 | — |
| Fever of unknown origin | 12 | 8 | — |
| Febrile days over 38°C, median no. (range) | 4 (1-17) | 4 (1-38) | .83 |
| Death due to infection, no. patients | 0 | 2 | .25 |
| . | G-CSF− group . | G-CSF+ group . | P . |
|---|---|---|---|
| n | 47 | 48 | — |
| No. of patients with documented infections*; severe infection, grade 3 or 4 | 19; 5 | 28; 8 | .07; .30 |
| Accumulated number of infectious events† | 31 | 39 | .07 |
| Bacteremia | 5 | 7 | — |
| Pneumonia | 1 | 3 | — |
| Upper respiratory tract infection | 5 | 6 | — |
| Intestinal infection | 2 | 4 | — |
| Urinary tract infection | 1 | 0 | — |
| Genital infection | 0 | 2 | — |
| Cellulitis | 1 | 2 | — |
| Herpes zoster | 1 | 0 | — |
| Herpes simplex | 2 | 4 | — |
| Fungal infection | 0 | 3 | — |
| Gingivitis | 1 | 0 | — |
| Fever of unknown origin | 12 | 8 | — |
| Febrile days over 38°C, median no. (range) | 4 (1-17) | 4 (1-38) | .83 |
| Death due to infection, no. patients | 0 | 2 | .25 |